CUMBERLAND PHARMACEUTICALS INC 2026: Revenue $166.46K, EPS ($0.29) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Cumberland Pharmaceuticals reported Q1 2026 results with revenue of $166.46K, down 56.3% YoY, and a net loss of $4.28M. The decline reflects the strategic sale of its branded portfolio to Apotex for ~$100 million, shifting focus to development-stage programs. Proceeds funded a special dividend and pipeline investments. Key highlights include positive Phase 2 data for Ifetroban in Duchenne muscular dystrophy and oncology metastasis prevention.
Cumberland Pharmaceuticals Inc reported first-quarter 2026 results showing sharply lower revenue and a wider net loss versus the prior-year quarter, reflecting the company's transition after the sale of its branded portfolio and ongoing investment in development-stage programs.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $166.46K | $380.8K | (56.3%) |
| Net income² | ($4.28M) | ($740.74K) | (477.3%) |
| Diluted EPS³ | ($0.29) | ($0.05) | (480%) |
¹ Reported as “Net revenues from continuing operations”. ² Reported as “Net income (loss) attributable to common shareholders”. ³ Reported as “Income (loss) per share attributable to common shareholders”.
Business Highlights
- Completed strategic sale of its branded FDA-approved portfolio to Apotex, repositioning the company to focus on pipeline and development-stage operations.
- Ifetroban advanced across multiple Phase 2 programs — notably breakthrough results in Duchenne muscular dystrophy (DMD) with ongoing enrollment in DMD, systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF) studies.
- Positive safety and trend findings were reported in a Phase 2 oncology metastasis prevention study, indicating potential reduced recurrence.
- Received approximately $100 million in proceeds from the portfolio sale, enabling a special dividend, funding of development programs, and support for CET incubation activities.
Original SEC Filing: CUMBERLAND PHARMACEUTICALS INC [ CPIX ] - 10-Q - Aug. 07, 2026